Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>BELL STEVEN J</u>						2. Issuer Name and Ticker or Trading Symbol BIOSANTE PHARMACEUTICALS INC								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
						BPA]								X Officer below)	(give title		Other (s below)	specify	
(Last) (First) (Middle) 111 BARCLAY BOULEVARD SUITE 280						3. Date of Earliest Transaction (Month/Day/Year) 04/11/2005								VP Re	VP Research & Pre Clinical Dev				
(Street)						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
LINCOLNSHIRE IL 60069														X Form filed by One Reporting Person Form filed by More than One Reporting					
(City) (State) (Zip)					-										Person				
		Tab	le I - No	n-Deri	ivativ	e Se	curi	ties Ac	quirec	l, Di	sposed o	f, or Be	neficia	ly Owned	l				
				Date	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		Disposed	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		Benefici Owned	es ally Following	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)	
Common Stock 0-					11/2005				М		12,500) A	\$2.9	13	,875		D		
Common Stock 04/				04/1	1/2005	2005					5,400	D	\$4.20	63 8,	475		D		
Common Stock 04/12/					2/2005	005			S		3,500	D	\$4.1	2 4,	975		D		
		-	Гable II -								oosed of, converti			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemo Execution if any (Month/Da	Date,	4. Transaction Code (Instr. 8)				6. Date Expirati (Month/	on Da		of Securities		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	Owner Form Direct or Ind (I) (In:	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares						
Employee Stock Option (right to	\$2.9	04/11/2005			M			12,500	(1)		04/20/2005	Common Stock	12,500	\$2.9	0		D		

Explanation of Responses:

buy)

1. This option has fully vested.

/s/ Steven J. Bell, Ph.D., by

Phillip B. Donenberg, attorney- 04/12/2005

in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.